Teva Wraps Up $703M Sale of Global Women’s Health Biz to CVC Capital Post author:Sam Post published:January 31, 2018 Post category:BioPharma The portfolio includes Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and additional products. Source: BioSpace You Might Also Like 3 Depressed Biotechs that Investors with a Long-Term Perspective Should Buy Right Now April 11, 2016 VolitionRX Announces The Formation Of March 19, 2017 How This Drug Candidate Could be a Winner in Gilead's Pipeline March 20, 2017